PEDIATRICS Vol. 92 No. 3 September 1993, pp. 474-476
This Article
Right arrow Full Text (PDF)
Right arrow This Policy is No Longer Valid.
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation

Routine Evaluation of Blood Pressure, Hematocrit, and Glucose in Newborns

Committee on Fetus and Newborn

It is the practice in many newborn nurseries to measure routinely, upon admission, each neonate's blood pressure by cuff oscillometry, blood glucose level by Dextrostix or Chemstrips, and hematocrit value via heel stick. Blood pressure is measured to screen for hypertension or hypotension; blood glucose, for hypoglycemia; and hematocrit, for anemia or polycythemia.

The routine testing of all newborns for a particular disorder before clinical manifestations are evident (universal screening) should result in a positive benefit-cost ratio. The following criteria should be considered in evaluating the benefit-cost ratio for any universal screening.

Incidence. There should be a high enough incidence of the disorder to justify screening for it unless the outcome of the disorder, if left undetected and untreated, would result in such significant morbidity that even with a relatively low incidence the benefit-cost ratio of screening would be positive (eg, phenylketonuria screening).

Methodology. The screening methodology should have a very high sensitivity so that there will be no, or a very low percentage of, subjects reported as being negative who are actually positive. The methodology should also have a high specificity so that there will be relatively few infants who are reported as being positive who are actually negative. The specificity need not be as high as the sensitivity since a true-positive test can be confirmed using a more specific methodology. In addition, the methodology should be relatively simple, cost-effective, accurate, and reproducible.

Natural History. The disorder for which infants are being screened should be a clearly defined entity with a well-described natural history.

Submitted on June 7, 1993
Accepted on June 8, 1993




This article has been cited by other articles:


Home page
 Arch. Dis. Child. Fetal Neonatal Ed.Home page
E M Dempsey and K Barrington
Short and long term outcomes following partial exchange transfusion in the polycythaemic newborn: a systematic review
Arch. Dis. Child. Fetal Neonatal Ed., January 1, 2006; 91(1): F2 - F6.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child. Fetal Neonatal Ed.Home page
H T Ho, W K Y Yeung, and B W Y Young
Evaluation of "point of care" devices in the measurement of low blood glucose in neonatal practice
Arch. Dis. Child. Fetal Neonatal Ed., July 1, 2004; 89(4): F356 - F359.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child. Fetal Neonatal Ed.Home page
M Watkinson
Hypertension in the newborn baby
Arch. Dis. Child. Fetal Neonatal Ed., March 1, 2002; 86(2): F78 - F81.
[Abstract] [Full Text] [PDF]

Home page
 CLIN PEDIATRHome page
L. Meloy, G. Miller, M. H. Chandrasekaran, C. Summitt, and G. Gutcher
Accuracy of Glucose Reflectance Testing for Detecting Hypoglycemia in Term Newborns
Clinical Pediatrics, November 1, 1999; 38(12): 717 - 724.
[Abstract] [PDF]

Home page
 CLIN PEDIATRHome page
L. P. Halamek and D. K. Stevenson
Neonatal Hypoglycemia, Part II: Pathophysiology and Therapy
Clinical Pediatrics, January 1, 1998; 37(1): 11 - 16.
[Abstract] [PDF]